NCT01683305
Unknown
Not Applicable
Biomarker Breast Pap Test
Silbiotech0 sites500 target enrollmentMarch 2013
ConditionsTumors
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Tumors
- Sponsor
- Silbiotech
- Enrollment
- 500
- Last Updated
- 13 years ago
Overview
Brief Summary
This will be a Phase I study. During the Phase I study, our goals are: 1) screen a number of cancer biomarkers in Nipple Aspirate Fluid (NAF) from women who have no mammographically detectable tumors, and those who have detectable tumors, 2) identify all the detectable markers and 3) establish that biomarkers detected in NAF could also be detected in the biopsied tumor tissue that was removed for diagnostic purpose in subjects who have detectable tumors.
Investigators
Indira Poola, Ph.D
Principal Investigator
Silbiotech
Eligibility Criteria
Inclusion Criteria
- •Any female subject aged 18 years or older
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Prospective Screening for Breast Cancer-related LymphedemaLymphedemaNCT01521741Massachusetts General Hospital10,000
Completed
Phase 1
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second RelapsePatients With Multiple Myeloma Experiencing aFirst or Second RelapseNCT01217203Innate Pharma15
Completed
Not Applicable
Intervention to Promote Breast Cancer Screening Among American Indian WomenBreast CancerNCT05530603University of South Dakota133
Terminated
Not Applicable
An In-vitro Standardization of B Cell Elispot AssaysTransplant SensitizationPanel Reactive AntibodySensitization to HLA AntigensNCT01334281Northwestern University19
Completed
Phase 1
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell CarcinomaRenal Cell CarcinomaUrinary Bladder NeoplasmsNCT02619253Nabil Adra52